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The field of breast cancer had witnessed clear improvements in survival and less morbidity over the last few
decades owing to earlier detection as a result of public awareness and screening, as well as treatments involving
the disciplines of surgical, radiation and medical oncology along with advances in imaging and pathological
diagnostics. However, in the last 5–10 years, newer assays and biological therapies have begun to cross new
boundaries with higher rates of cure seen in more aggressive cancers. Even though metastatic breast cancer
remains incurable, some, but not all, subsets of patients with breast cancer are living longer and more productive
lives. Many challenges still remain, and the development of team science coupled with collaborative clinical
research and care is expected to accelerate advances along this trajectory.
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Introduction
The one-year anniversary of our Spotlight on breast can-
cer collection is a timely opportunity to review the snap-
shot of accomplishments in research and new care
standards represented in this series of original articles
and reviews. Global interest in breast cancer owing to its
commonality and its growing incidence has created a
surge in research funding and scientific output that is
now being translated into clinical gains. Relative mortal-
ity and morbidity have clearly been favorably impacted,
but recurrence and incurability of advanced disease re-
main problematic. Specific drivers of cancer initiation,
progression, metastasis, and drug resistance are elusive,
and their interactions with normal biological pathways
are complex and highly individualized to both tumor
biology and host factors. The convergence of data-dense
analytical technologies in genomics, transcriptomics,
epigenetics, and proteomics, with linkage to well-
annotated human tissue sets and prospective clinical tri-
als, have begun to yield new information and insights. In
our breast cancer collection, we attempt to provide ex-
amples that stitch together the larger picture of where
we have been and where we are going. The goalpost
should be crystal clear—better clinical outcomes, in
terms of both survival and quality of life.
The connection of estrogen and breast cancer:
from prevention to treatment
In breast cancer, hormone receptor pathways, initially
targeted as far back as 1896 with the first report of a
clinical response to oophorectomy, remain a key focus
of newer discoveries [1]. This is expected, because can-
cers are a distillation of continuous selection of the fit-
test from cumulative genetic and epigenetic insults, and
the normal cellular “toolkit” is the most likely to be co-
opted in this process. In the case of breast cells, estrogen
is a key developmental and growth stimulus—the cell is
essentially programmed to respond to estrogen. Assum-
ing the stepwise (or parallel) model of serial random (or
possibly biased) alterations leading to cancer, it would
stand to reason that many of these events will involve
the estrogen receptor signaling apparatus. Moreover,
these phases would range from early pre-neoplasia to
late events such as invasion and metastasis.
Might suppression of estrogen pathways therefore
yield a preventive effect, just like statins and antihyper-
tensive agents are postulated to lower the risk of
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coronary disease? Oophorectomy is clearly associated
with a lower risk of breast cancer, albeit at a cost of
symptoms and possible longer-term effects of estrogen
deficiency, such as osteoporosis [2]. In our breast cancer
series, Vogel summarizes the long history of the devel-
opment of selective estrogen receptor modulators
(SERMs) as breast cancer treatment and, ultimately, pre-
vention [3]. In the case of invasive breast cancer, SERMs
and aromatase inhibitors, through different mechanisms,
reduce recurrence of breast cancer by one half and mor-
tality by one third. In the preventive setting, however,
the pivotal trials could not practically be powered for
survival impacts. Yet this raises the key question as to
whether these preventive therapies are simply delaying
the clinical onset of breast cancer or actually preventing
it. It may not make a difference to the individual whose
cancer is delayed as to never surface clinically in their
lifetime. However, hormonal suppression may simply shift
selective pressures in other directions—as suggested by re-
cent preliminary findings of non-significantly higher estro-
gen receptor-negative breast cancer rates in the IBIS-I
tamoxifen prevention trial [4]. Still, a 30–50 % reduction
in breast cancer with 5 years of preventive therapy, con-
sistent across multiple trials, is a big public health triumph
given the morbidity associated with treatments. But even
though tamoxifen and raloxifene are approved and rec-
ommended for breast cancer prevention for those at
even modestly elevated risk, they are remarkably under-
utilized [5]. Ongoing refinements of SERMs designed to
impact other estrogen-associated outcomes, primarily
bone and cardiovascular, are a priority, yet challenging
given the size and follow times required of the trials.
Development of more sophisticated risk models and
validated surrogate biomarkers may allow for more effi-
ciently designed trials in the future.
There is overwhelming evidence that adjuvant hormonal
therapy with tamoxifen and aromatase inhibitors have im-
proved mortality from hormone receptor-positive early
stage breast cancer [6, 7]. Predictors of response other than
quantitative measures of estrogen receptor expression [8],
however, remain obscure. Artigalás et al. [9] present a sys-
tematic review and meta-analysis of inherited polymor-
phisms of CYP19A1, the gene encoding aromatase. This
enzyme is present in peripheral tissue—particularly in adi-
pose tissue—and converts androgens to estrogens as the
primary source of these hormones in postmenopausal
women (and men). Serum estrogen levels are therefore re-
lated to body mass index, a known risk factor for breast
cancer and breast cancer recurrence—even possibly in
male breast cancer as suggested by Humphries et al. [10].
Hence, it is postulated that certain inherited functional var-
iants of CYP19A1 are related to estrogen levels, risk of
breast and uterine cancer, and outcomes in hormone
receptor-positive breast cancer [11–13]. This overview of
12 studies, which included early, neoadjuvant, and ad-
vanced stage cohorts, showed that the rs4646 single
nucleotide polymorphism (SNP) was associated with
approximately a doubling time to disease progression,
while associations seen with other SNPs in individual
studies did not emerge as significant [9]. This study by
Artigalás et al. illustrates the need to assess large numbers
of studies to make genomic–phenotype associations from
broad-scale searches. Their study was limited in size and
also by the fact that many SNPs were only reported in one
or few of the studies. In addition, associations from data
mining exercises need to be confirmed functionally in
cell-based or animal models, with the acknowledgement
that these are also not perfect and could in fact miss im-
portant drivers of physiological behavior. Then, further
supportive validation needs to be made, preferably from
prospective controlled trials.
In the metastatic setting, tamoxifen and aromatase in-
hibitors, along with the estrogen receptor down-regulator
fulvestrant are all effective in transiently halting progres-
sion of disease, although resistance ultimately develops
with a wide range of median times to disease progression
among patients. Migliaccio et al. have reviewed the evolu-
tion of hormonal therapies and more recent developments
in combinations of different hormonal therapies [14]. Sev-
eral pathways have been shown to interact with those me-
diated by the estrogen receptor, primarily growth-factor
pathways as well as the central control of the cell cycle,
which are also intimately tied to growth and metabolic
pathways as well as multiple other inputs. The last few
years have witnessed the development of several drugs
that modulate these pathways and augment the clinical
benefit of hormonal blockade. Yamamoto-Ibusuki et al.
have summarized the background and recent trial results,
showing doubling of progression-free survival but, inter-
estingly, no impact on overall survival from the addition
of the mTOR inhibitor everolimus to aromatase inhibitor
therapy [15–17]. More recently, the cyclin-dependent
kinase 4/6 inhibitor palbociclib has been shown to pro-
duce even larger augmentations of progression-free sur-
vival—both in the first-line setting when added to
letrozole [18] and in the second-line setting when
added to fulvestrant [19], but, again, without survival
benefits at this point in follow-up, possibly due to the
limited number of deaths seen so far. Both everolimus
and palbociclib are in or entering trials in the adjuvant
setting—these finding are eagerly awaited to address
the critical questions as to whether metastases and death
from breast cancer can be lowered with acceptable toxic-
ities over and above the remarkable gains already achieved
with hormonal therapy alone. As Yamamoto-Ibusuki et al.
point out, much more work is needed to decipher other
components of the PI3K/Akt/mTOR pathway as newer
drugs directly inhibit PI3K, or specifically the p110α
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catalytic subunit that commonly harbors activating muta-
tions, as well as Akt enter clinical testing.
The theme of body mass and energy balance ties in
not only to circulating estrogens, but also metabolic
pathways involving AMP-activated protein kinase and
mTOR as well as metabolic pathways mediated by insu-
lin and insulin like-growth factors. All of these networks
have been implicated in cancer development and pro-
gression, with recurrent mutations in these pathways
seen in diverse cancer types. Many organizations are
now recommending a “heart-healthy” lifestyle to lower
the risk of cancer and recurrence for many tumor types
[20], but optimal exercise and diet regimens remain un-
defined, and controlled prospective trials with recur-
rence and mortality endpoints are lacking. However,
there are other potential benefits of exercise including
management fatigue and other quality of life indices,
particularly in patients receiving chemotherapy, There
has been interest in developing and formally testing spe-
cific exercise regimens that vary based on intensity, dur-
ation, and other factors [21]. Travier et al. reported on
an a usual care-controlled 18-week supervised program
of aerobic and strength exercise with cognitive behav-
ioral support during chemotherapy for early stage breast
cancer and found no effect on the primary endpoint of
fatigue, but did show less of an increase in fatigue with
chemotherapy [22]. Such studies are critical to define
optimal approaches and methods to individualize physical
activity regimens. Also, long-term sustainability of lifestyle
interventions must be achieved for any long-term impact
on quality of life and cancer control endpoints.
Deciphering growth factor pathways and
associated networks
In addition to estrogen pathways, other known key
breast carcinogenesis drivers include growth factor re-
ceptor pathways (e.g., HER2) as well as DNA repair defi-
ciency, which is both an acquired as well as an inherited
genotype and phenotype. Targeting the HER2 receptor
in the 20 % of cancers in which HER2 is amplified and
overexpressed has also improved outcome in the adju-
vant setting, comparable to the improvement seen with
hormonal therapy, with the use of 1 year of the human-
ized anti-HER2 antibody trastuzumab [23]. Predictors of
benefit and markers of resistance have been described
[24], but not widely confirmed and validated; hence,
none are used in the clinic to help guide therapy (other
than the determination of HER2 status itself ). The use
of multiparametric analysis at the genomic, gene expres-
sion, and proteomic levels, along with bioinformatics ana-
lysis, can discern patterns and identify biological pathways
that may not only predict responsiveness, but point to
therapeutic targets that could be addressed pharmacologic-
ally to augment activity and reverse clinical resistance. This
requires that the samples analyzed are sufficient in number
and, ideally, derived from a clinical trial where patients
were randomized to receive or not receive the therapy in
question. Sonnenblick et al. described an original finding
after interrogating tissue samples from a prospective ran-
domized trial (FinHER), an institutional cohort, and The
Cancer Genome Atlas (TCGA), using gene expression and
reverse phase protein array analysis [25]. Their computa-
tional plan focused on developing a signal transducer and
activator of transcription 3 protein (STAT3) signature that
was derived from the institutional dataset and validated on
TCGA data, and then tested for its ability to predict distant
recurrence on both the institutional and FinHER datasets.
The results showed that activated (phosphorylated) STAT3
did not predict outcome, but the signature did—a theme
that is repeating in the field of prognostic and predictive
biomarkers, specifically, the notion that a pathway signa-
ture rather than any specific component might be a better
way to link biology to outcome. In fact, this is being
reflected in newer classifications of breast cancer that are
based on gene expression and other signatures. Determin-
ing whether these will ultimately replace conventional sin-
gle biomarkers need await more studies, most importantly
those that are linked to prospective trials that are increas-
ingly being developed with parallel multiparametric cor-
relative studies.
The Spotlight on breast cancer collection illustrates
trends in breast cancer basic, translational, and clinical
sciences and highlights the blurring lines and interac-
tions between laboratory and clinical investigation that
will be necessary to move the field forward. Continued
technological advances coupled with a commitment to
making every clinical trial not only generate clinical out-
comes but also biological readouts that can be integrated
to fashion newer strategies will be essential in our goal
to help patients with breast cancer live longer and fuller
lives.
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